Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-285-2 | CAS number: 12158-74-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Study was performed between 23/11/2010 and 07/12/2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- The test species used in this study was mice. The test guideline states that the preferred rodent species is rat; however the guideline also states that other rodent species may also be used and as such this is not considered to be a deficiency.
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Dicopper hydroxide phosphate
- EC Number:
- 235-285-2
- EC Name:
- Dicopper hydroxide phosphate
- Cas Number:
- 12158-74-6
- Molecular formula:
- Cu2HO5P
- IUPAC Name:
- dicopper hydroxide phosphate
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): dicopper hydroxide phosphate
-CAS Number: 12158-74-6
- EC Number: 235-285-2
- Purity test date: 15/01/2009
- Lot/batch No.: 08004
- solid: particulate/powder
Test animals
- Species:
- mouse
- Strain:
- Balb/c
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: BIOSERV
- Age at study initiation: no data
- Weight at study initiation: 17.8 g - 21.2 g
- Fasting period before study: 3 hours
- Housing: no data
- Diet (e.g. ad libitum): ad libitum, no diet 3 hours before and 1 hour after application
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 - 23°C
- Humidity (%): 40 - 60%
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12 hours light/dark cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Test solution and vehicle (distilled water were administered by force-feeding under a volume of 2 ml/100 g bodyweight, using a suitable graduated syringe fitted with an oesophageal metal cannula.
- Doses:
- 300 mg/kg bw
2000 mg/kg bw - No. of animals per sex per dose:
- 3 females per dose.
6 females in control groups. - Control animals:
- yes
- Remarks:
- All control animal recieved the vehicle (distilled water).
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: weighed on Day 0, Day 7 and Day 14.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs and body weight
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 2 animals treated with 2000 mg/kg bodyweight died between day 1 and day 14.
None of the animals treated with 300 mg/kg bodyweight died during the 14 day observation period. - Clinical signs:
- other: See tables below.
- Gross pathology:
- See tables below.
Any other information on results incl. tables
Test series 1 – Animals treated with 2000 mg/kg bw
Table 1: Clinical observations from T0 to 4 hours
Observation |
Test group 1 (2000 mg/kg bw) |
Control group 1 (vehicle |
||||
Animal 1 |
Animal 2 |
Animal 3 |
Animal 1 |
Animal 2 |
Animal 3 |
|
Spontaneous activity |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Preyer’s reflex (noise) |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Respiratory rate |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Convulsions |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Tremors |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Body temperature (evaluated by touch) |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Muscle tone |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Palpebral opening |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Pupil appearance |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Salivation |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Lachrymation |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Righting reflex |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Back hair appearance |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
MORTALITY |
0 |
0 |
0 |
0 |
0 |
0 |
NAD = No abnormalities noted
Table 2: Clinical observations from day 1 to day 14
Observation |
Test group 1 (2000 mg/kg bw) |
Control group 1 (vehicle) |
||||
Animal 1 |
Animal 2 |
Animal 3 |
Animal 1 |
Animal 2 |
Animal 3 |
|
Spontaneous activity |
Decreased |
Decreased |
NAD |
NAD |
NAD |
NAD |
Preyer’s reflex (noise) |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Respiratory rate |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Convulsions |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Tremors |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Body temperature (evaluated by touch) |
Decreased |
Decreased |
NAD |
NAD |
NAD |
NAD |
Muscle tone |
Decreased |
Decreased |
NAD |
NAD |
NAD |
NAD |
Palpebral opening |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Pupil appearance |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Salivation |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Lachrymation |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Righting reflex |
Limited |
Limited |
NAD |
NAD |
NAD |
NAD |
Back hair appearance |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
MORTALITY |
1 |
1 |
0 |
0 |
0 |
0 |
NAD = No abnormalities noted
Table 3: body weight and weight gain in grams
Day |
Test group 1 (2000 mg/kg bw) |
Control group 1 (vehicle) |
||||
Animal 1 |
Animal 2 |
Animal 3 |
Animal 1 |
Animal 2 |
Animal 3 |
|
Day 0 |
21.2 |
20.6 |
20.5 |
18.6 |
19.4 |
17.8 |
Day 7 |
n/a |
n/a |
17.4 |
20.3 |
20.2 |
21.0 |
Day 7 – Day 0 |
n/a |
n/a |
-3.1 |
1.7 |
0.8 |
3.2 |
Day 14 |
n/a |
n/a |
17.1 |
20.8 |
21.0 |
20.9 |
Day 14 – Day 0 |
n/a |
n/a |
-3.4 |
2.2 |
1.6 |
3.1 |
n/a = not applicable due to early mortality.
Table 4: macroscopic observation at necropsy
Observed Organs |
Test group 1 (2000 mg/kg bw) |
Control group 1 (vehicle) |
||||
Animal 1 |
Animal 2 |
Animal 3 |
Animal 1 |
Animal 2 |
Animal 3 |
|
Oesophagus |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Stomach |
1, 2 |
1, 3 |
NAD |
NAD |
NAD |
NAD |
Duodenum |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Jejunum |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Ileum |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Caecum |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Colon |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Rectum |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Spleen |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Liver |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Thymus |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Trachea |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Lungs |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Heart |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Kidneys |
NAD |
NAD |
4 |
NAD |
NAD |
NAD |
Urinary bladder |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Ovaries |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Uterus |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Adrenals |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
Pancreas |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD |
NAD = No abnormality detected
1. Strong gas development
2. Test material still visible in stomach 2 days after application
3. Test material still visible in stomach 3 days after application
4. Atypical appearance of kidneys (yellow) due to restricted blood flow
[SEE 'OVERALL REMARKS, ATTACHMENTS' FOR DATA RELATING TO ANIMALS TESTED WITH 300 MG/KG BW]
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The LD50 of dicopper hydroxide phosphate has been determined to be in the range of > 300 to < 2000 mg/kg bw.
- Executive summary:
The LD50 of dicopper hydroxide phosphate has been determined to be in the range of > 300 to < 2000 mg/kg bw and as such is classified as acutely toxic via the oral route, category 4 (EU CLP). This study has been selected as the key study in accordance with Regulation (EC) No. 1907/2006 (REACH) because the results are sufficient in order to derive a reliable conclusion on classification and labelling in accordance with Regulation (EC) No. 1272/2008 (EU CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.